Studies in breast cancer models have shown that combining CDK4/6 and PI3K inhibitors can prevent resistance to PI3K inhibitors while also stopping cancer cells from adapting to CDK4/6 inhibitors [22,23,24,25]. Here, CDK4 is linked to cancer.